Live Chat: SERD Surge with Dr. Sherry Shen

Host Victoria, with Dr. Sherry Shen and co-host Ellen, delivers a concise, patient-focused overview of oral SERDs in HR+ metastatic breast cancer—covering ESR1 mutations, key trials (evERA, SERENA‑6), FDA‑approved agents, side-effect management, and treatment implications. This is the first episode in our Live Chats series. Bonus clip: Rebecca Shatsky, MD, previews the evERA trial and her excitement about combining capivasertib with oral SERDs.